Nyrada (ASX:NYR)

Executive Summary

Nyrada is an Australian public biotech (ASX:NYR) pioneering first-in-class TRPC ion-channel blockers using a benzopyran scaffold. Its lead candidate, Xolatryp, is under Phase 1 development for cardioprotection and neuroprotection, targeting acute coronary syndrome and stroke. The platform's ability to modulate multiple TRPC channels extends to lipid lowering, pain, and autoimmune diseases, offering a broad therapeutic potential. Founded in 2020 and operating leanly with 10-50 employees, Nyrada leverages its public listing for capital access. Despite early-stage risks, the company's differentiated mechanism and intellectual property position provide speculative upside. Upcoming catalysts include Phase 1 data for Xolatryp in H1 2026, which will be pivotal for proof-of-concept. Additional progress in preclinical lipid-lowering and pain programs may also unlock value, making Nyrada a high-risk, high-reward opportunity for investors seeking novel ion-channel modulation.

Upcoming Catalysts (preview)

• Q2 2026Initial safety and pharmacokinetic data from Phase 1 trial of Xolatryp in acute coronary syndrome65% success
• Q3 2026IND submission for lead lipid-lowering program (TRPC5 inhibitor)40% success
• Q4 2026Preclinical results for pain program (TRPC1/4/5 modulator)50% success